Vol 4 (June 25, 2026): AME Clinical Trials Review

The dry retina paradox: interpreting MERLIN in clinical practice

Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2

Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon

We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer

Precision in practice: a new standard in early-relapsing HR+ breast cancer

Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)

EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer

Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?

Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study

Extensive-stage small cell lung cancer: progress, slowly but surely